[{"data":1,"prerenderedAt":212},["ShallowReactive",2],{"drug-lamotrigine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":61,"contraindications":95,"warnings":114,"renal":115,"monitoring":116,"interactions":117,"review":118,"examples":121,"atc":122,"iran":124,"links":156,"populations":173,"usApproval":207},"lamotrigine",1,{"fa":7,"en":8},"لاموتریژین","Lamotrigine","nervous-system",{"fa":11,"en":12},"ضدتشنج \u002F تثبیت‌کننده خلق","Anticonvulsant \u002F mood stabiliser",[14],{"name":15,"market":16},"Lamictal","US",[18,19,7,20],"lamictal","لامیکتال","لاموتریجین",[22,37,45,53],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":32,"refs":33},"tab-25","odt","oral","25 mg tablet",{"amount":28,"unit":29,"perUnit":30,"scored":31},25,"mg","tablet",false,[16],[34],{"source":35,"section":36},"fda-lamotrigine","3",{"id":38,"form":24,"route":25,"label":39,"concentration":40,"markets":42,"refs":43},"tab-50","50 mg tablet",{"amount":41,"unit":29,"perUnit":30,"scored":31},50,[16],[44],{"source":35,"section":36},{"id":46,"form":24,"route":25,"label":47,"concentration":48,"markets":50,"refs":51},"tab-100","100 mg tablet",{"amount":49,"unit":29,"perUnit":30,"scored":31},100,[16],[52],{"source":35,"section":36},{"id":54,"form":24,"route":25,"label":55,"concentration":56,"markets":58,"refs":59},"tab-200","200 mg tablet",{"amount":57,"unit":29,"perUnit":30,"scored":31},200,[16],[60],{"source":35,"section":36},[62,82],{"id":63,"disease":64,"label":65,"population":68,"type":72,"unit":29,"dose":73,"refs":77},"bipolar","bipolar-maintenance",{"fa":66,"en":67},"دوقطبی (نگهدارنده) — بزرگسال","Bipolar maintenance — adults",{"minAge":69},{"value":70,"unit":71},18,"year","notCalculated",{"reason":74},{"fa":75,"en":76},"دوز هدف ۲۰۰ mg\u002Fday؛ با والپروات ۱۰۰ mg\u002Fday؛ با کاربامازپین\u002Fفنی‌توئین\u002Fفنوباربیتال بدون والپروات ۴۰۰ mg\u002Fday. افزایش دوز باید دقیقاً طبق جداول برچسب (بسته به والپروات یا القاکننده‌های آنزیمی) باشد تا خطر راش کشنده کم شود؛ Doz این جداول را محاسبه نمی‌کند.","Target 200 mg\u002Fday; with valproate 100 mg\u002Fday; with carbamazepine\u002Fphenytoin\u002Fphenobarbital without valproate 400 mg\u002Fday. Escalation must follow the label tables exactly (depends on valproate or enzyme inducers) to reduce the risk of fatal rash; Doz does not calculate these tables.",[78,80],{"source":35,"section":79},"2.4",{"source":35,"section":81},"2.4, Table 5",{"id":83,"disease":83,"label":84,"population":87,"type":72,"unit":29,"dose":88,"refs":92},"epilepsy",{"fa":85,"en":86},"صرع — بزرگسال و کودک","Epilepsy — adults and children",{},{"reason":89},{"fa":90,"en":91},"افزایش دوز باید دقیقاً طبق جداول برچسب (بسته به والپروات یا القاکننده‌های آنزیمی) باشد تا خطر راش کشنده کم شود؛ Doz این جداول را محاسبه نمی‌کند.","Escalation must follow the label tables exactly (depends on valproate or enzyme inducers) to reduce the risk of fatal rash; Doz does not calculate these tables.",[93],{"source":35,"section":94},"2.2, Tables 1–2",[96,105],{"id":97,"severity":98,"text":99,"refs":102},"ci","block",{"fa":100,"en":101},"حساسیت (راش، آنژیوادم، کهیر، زخم مخاطی) به لاموتریژین.","Hypersensitivity (rash, angioedema, urticaria, mucosal ulceration) to lamotrigine.",[103],{"source":35,"section":104},"4",{"id":106,"severity":107,"text":108,"refs":111},"rash","warn",{"fa":109,"en":110},"هشدار جعبه‌ای: راش جدی (SJS\u002FTEN)؛ در کودکان ۰٫۳ تا ۰٫۸٪. خطر با والپروات، دوز اولیه بالا یا افزایش سریع بیشتر است.","Boxed warning: serious rash (SJS\u002FTEN); 0.3–0.8% in children. Higher risk with valproate, high starting dose or rapid escalation.",[112],{"source":35,"section":113},"Boxed Warning",[],[],[],[],{"status":119,"reviewer":120,"date":120},"unverified",null,[],[123],"N03AX09",{"status":125,"forms":126,"refs":151},"registered",[127,131,135,139,143,147],{"code":128,"en":129,"fa":130},"02150","LAMOTRIGIN 10MG\u002FML ORAL SOLUTION","محلول خوراکی لاموتریجین ۱۰ میلی‌گرم \u002F میلی‌لیتر",{"code":132,"en":133,"fa":134},"00732","LAMOTRIGINE 100MG TAB","قرص لاموتریژین ۱۰۰ میلی‌گرم",{"code":136,"en":137,"fa":138},"17572","LAMOTRIGINE 200MG TAB","قرص لاموتریژین ۲۰۰ میلی‌گرم",{"code":140,"en":141,"fa":142},"01991","LAMOTRIGINE 25MG TAB","قرص لاموتریژین ۲۵ میلی‌گرم",{"code":144,"en":145,"fa":146},"00733","LAMOTRIGINE 50MG TAB","قرص لاموتریژین ۵۰ میلی‌گرم",{"code":148,"en":149,"fa":150},"11824","LAMOTRIGINE 600MG TAB","قرص لاموتریژین ۶۰۰ میلی‌گرم",[152],{"source":153,"section":154,"url":155},"darooyab-generic","G-668\u002FLamotrigine","https:\u002F\u002Fwww.darooyab.ir\u002FG-668\u002FLamotrigine",[157,161,165,168,171],{"kind":158,"url":159,"label":160},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=219677","ANDA219677",{"kind":162,"url":163,"label":164},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=83297e2e-9199-4b3d-9f44-a921787758fe","FDA Lamotrigine",{"kind":166,"url":167,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa695007.html",{"kind":169,"url":170,"label":123},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N03AX09",{"kind":172,"url":155,"label":8},"darooyab",{"pregnancy":174,"lactation":183,"pediatric":191,"geriatric":199},{"level":175,"text":176,"quote":179,"refs":180},"caution",{"fa":177,"en":178},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Data from several prospective pregnancy exposure registries and epidemiological studies of pregnant women have not detected an increased frequency of major congenital malformations or a consistent pattern of malformations among women exposed to lamotrigine compared with the general population (see Data ) .",[181],{"source":35,"section":182},"8.1",{"level":175,"text":184,"quote":187,"refs":188},{"fa":185,"en":186},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Lamotrigine is present in milk from lactating women taking lamotrigine orally disintegrating tablets (see Data ) .",[189],{"source":35,"section":190},"8.2",{"level":192,"text":193,"quote":196,"refs":197},"avoid",{"fa":194,"en":195},"هشدار جعبه‌ای برچسب درباره کودکان.","Boxed warning in the label about children.","The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.3% to 0.8% in pediatric patients (aged 2 years to 17 years) and 0.08% to 0.3% in adults receiving lamotrigine.",[198],{"source":35,"section":113},{"level":175,"text":200,"quote":203,"refs":204},{"fa":201,"en":202},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.",[205],{"source":35,"section":206},"8.5",{"kind":208,"refs":209,"id":160},"ANDA",[210],{"source":35,"section":211},"SPL approval \u002F marketing category",1792440738776]